Nutex Health Inc NUTX.OQ NUTX.O is expected to show a rise in quarterly revenue when it reports results on March 27 for the period ending December 31 2024
The Houston Texas-based company is expected to report a 16.4% increase in revenue to $81.125 million from $69.67 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Nutex Health Inc is for a loss of 12 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Nutex Health Inc is $60.00, above its last closing price of $59.50.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.20 | -0.24 | -1.72 | Missed | -616.7 |
Jun. 30 2024 | -0.29 | -0.29 | -0.07 | Beat | 75.9 |
Mar. 31 2024 | 0.00 | -0.60 | Missed | | |
Dec. 31 2023 | 0.00 | 0.00 | Met | ||
Sep. 30 2023 | -0.75 | -1.50 | Missed | -100 | |
Jun. 30 2023 | -1.50 | -0.75 | -1.50 | Missed | -100 |
Mar. 31 2023 | -2.26 | -2.25 | -1.50 | Beat | 33.3 |
Dec. 31 2022 | -2.36 | -2.25 | -3.00 | Missed | -33.3 |
This summary was machine generated March 25 at 20:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)